{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:52:01Z","timestamp":1790621521163,"version":"4.1.0"},"reference-count":37,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2017,1,4]],"date-time":"2017-01-04T00:00:00Z","timestamp":1483488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Thoracic cancers, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and malignant pleural mesothelioma (MM), cause the highest rate of cancer mortality worldwide. Most of these deaths are as a result of NSCLC; however, prognoses for the other two diseases remain as some of the poorest of any cancers. Recent advances in immunotherapy, specifically immune checkpoint inhibitors, have begun to help a small population of patients with advanced lung cancer. People who respond to these immune therapies generally have a durable response and many see dramatic decreases in their disease. However, response to immune therapies remains relatively low. Therefore, intense research is now underway to rationally develop combination therapies to expand the range of patients who will respond to and benefit from immune therapy. One promising approach is with oncolytic viruses. These oncolytic viruses (OVs) have been found to be selective for or have been engineered to preferentially infect and kill cancer cells. In pre-clinical models of different thoracic cancers, it has been found that these viruses can induce immunogenic cell death, increase the number of immune mediators brought into the tumor microenvironment and broaden the neoantigen-specific T cell response. We will review here the literature regarding the application of virotherapy toward augmenting immune responses in thoracic cancers.<\/jats:p>","DOI":"10.3390\/biomedicines5010002","type":"journal-article","created":{"date-parts":[[2017,1,4]],"date-time":"2017-01-04T09:39:32Z","timestamp":1483522772000},"page":"2","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Viroimmunotherapy of Thoracic Cancers"],"prefix":"10.3390","volume":"5","author":[{"given":"Alexander","family":"Dash","sequence":"first","affiliation":[{"name":"Department of Biology, Macalester College, St. Paul, MN 55105, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, Minneapolis, MN 55455, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2017,1,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMe1205943","article-title":"Tumor immunotherapy directed at PD-1","volume":"366","author":"Ribas","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Evan, W., Alley, L.R.M., Santoro, A., Becky, K., Yuan, S., Cheng, J.D., Piperdi, B., and Schellens, J.H.M. (2015, January 18\u201322). Abstract CT103: Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: Preliminary results from KEYNOTE-028. Proceedings of the 106th Annual Meeting of the American Association for Cancer Research, Philadelphia, PA, USA.","DOI":"10.1158\/1538-7445.AM2015-CT103"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Antonia, S.J., Lopez-Martin, J.A., Bendell, J.C., Ott, P.A., Taylor, M.H., Eder, J.P., Jager, D., Le, D.T., De Braud, F.G., and Morse, M. (2016, January 3\u20137). Checkmate 032: Nivolumab (N) alone or in combination with ipilimumab (I) for the treatment of recurrent small cell lung cancer (SCLC). Proceedings of the American Society of Clinical Oncology Annual Meeting, Chicago, IL, USA.","DOI":"10.1200\/JCO.2016.34.15_suppl.100"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.trsl.2012.12.010","article-title":"Oncolytic virus therapy for cancer: the first wave of translational clinical trials","volume":"161","author":"Patel","year":"2013","journal-title":"Transl. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3389\/fonc.2014.00074","article-title":"Oncolytic immunotherapy: Dying the right way is a key to eliciting potent antitumor immunity","volume":"4","author":"Guo","year":"2014","journal-title":"Front. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"33165","DOI":"10.18632\/oncotarget.5320","article-title":"Vesicular stomatitis virus expressing interferon-beta is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer","volume":"6","author":"Patel","year":"2015","journal-title":"Oncotarget"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/hum.2009.088","article-title":"Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy","volume":"21","author":"Saloura","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1158\/1078-0432.CCR-07-0403","article-title":"A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses","volume":"13","author":"Sterman","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_11","first-page":"6201","article-title":"Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity","volume":"61","author":"Odaka","year":"2001","journal-title":"Cancer Res."},{"key":"ref_12","first-page":"S272","article-title":"Endobronchial ultrasound elastography: A new method in endobronchial ultrasound-guided transbronchial needle aspiration","volume":"7","author":"Jiang","year":"2015","journal-title":"J. Thorac. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/cncr.29856","article-title":"Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors","volume":"122","author":"Lam","year":"2016","journal-title":"Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1476-4598-8-47","article-title":"Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells","volume":"8","author":"Sei","year":"2009","journal-title":"Mol. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/mt.2011.228","article-title":"Treating tumors with a vaccinia virus expressing IFNbeta illustrates the complex relationships between oncolytic ability and immunogenicity","volume":"20","author":"Wang","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"7713","DOI":"10.1158\/0008-5472.CAN-09-1013","article-title":"Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma","volume":"69","author":"Willmon","year":"2009","journal-title":"Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/cgt.2010.10","article-title":"Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy","volume":"17","author":"Li","year":"2010","journal-title":"Cancer Gene Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.surg.2015.01.006","article-title":"Oncolytic adenovirus expressing interferon alpha in a syngeneic Syrian hamster model for the treatment of pancreatic cancer","volume":"157","author":"LaRocca","year":"2015","journal-title":"Surgery"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1756-9966-29-52","article-title":"Potent anti-tumor activity of telomerase-dependent and HSV-TK armed oncolytic adenovirus for non-small cell lung cancer in vitro and in vivo","volume":"29","author":"Zhang","year":"2010","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/mt.2015.115","article-title":"Viral infection of tumors overcomes resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses","volume":"23","author":"Woller","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/jgm.1486","article-title":"Complete regression of human malignant mesothelioma xenografts following local injection of midkine promoter-driven oncolytic adenovirus","volume":"12","author":"Kubo","year":"2010","journal-title":"J. Gene Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1158\/0008-5472.CAN-11-3185","article-title":"Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma","volume":"72","author":"Miyamoto","year":"2012","journal-title":"Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3109\/07357907.2012.654870","article-title":"Angiogenesis inhibition using an oncolytic herpes simplex virus expressing endostatin in a murine lung cancer model","volume":"30","author":"Goodwin","year":"2012","journal-title":"Cancer Investig."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/1743-422X-10-241","article-title":"MicroRNA-145 regulates oncolytic herpes simplex virus-1 for selective killing of human non-small cell lung cancer cells","volume":"10","author":"Li","year":"2013","journal-title":"Virol. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/jgm.877","article-title":"Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses","volume":"8","author":"Adusumilli","year":"2006","journal-title":"J. Gene Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1158\/0008-5472.CAN-07-6265","article-title":"Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response","volume":"68","author":"Gauvrit","year":"2008","journal-title":"Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1097\/JTO.0000000000000214","article-title":"Measles vaccine strains for virotherapy of non-small-cell lung carcinoma","volume":"9","author":"Patel","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6365","DOI":"10.18632\/oncotarget.2219","article-title":"Mitophagy promotes replication of oncolytic Newcastle disease virus by blocking intrinsic apoptosis in lung cancer cells","volume":"5","author":"Meng","year":"2014","journal-title":"Oncotarget"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3727\/096504011X13079697132880","article-title":"Antiproliferative effect of newcastle disease virus strain D90 on human lung cancer cell line A549","volume":"19","author":"Fu","year":"2011","journal-title":"Oncol. Res."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Campion, C.A., Soden, D., and Forde, P.F. (2016). Antitumour responses induced by a cell-based Reovirus vaccine in murine lung and melanoma models. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2536-2"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1158\/1535-7163.MCT-10-0590","article-title":"Reovirus virotherapy overrides tumor antigen presentation evasion and promotes protective antitumor immunity","volume":"9","author":"Gujar","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1245\/s10434-010-1239-1","article-title":"Impact of preoperative breast MRIs on timing of surgery and type of intervention in newly diagnosed breast cancer patients","volume":"17","author":"Angarita","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.surg.2013.06.004","article-title":"An oncolytic vaccinia virus expressing the human sodium iodine symporter prolongs survival and facilitates SPECT\/CT imaging in an orthotopic model of malignant pleural mesothelioma","volume":"154","author":"Belin","year":"2013","journal-title":"Surgery"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1089\/hum.2008.036","article-title":"Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma","volume":"19","author":"Kelly","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e955691","DOI":"10.4161\/21624011.2014.955691","article-title":"Consensus guidelines for the detection of immunogenic cell death","volume":"3","author":"Kepp","year":"2014","journal-title":"Oncoimmunology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1479-5876-11-20","article-title":"Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer","volume":"11","author":"Mader","year":"2013","journal-title":"J. Transl. Med."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/5\/1\/2\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:25:28Z","timestamp":1760207128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/5\/1\/2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,4]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,3]]}},"alternative-id":["biomedicines5010002"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines5010002","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,4]]}}}